

**VRL/SEC/EXCHANGE**

**29.01.2026**

<b>National Stock Exchange of India Ltd.</b> 5 <sup>th</sup> Floor, Exchange Plaza Bandra (E), Mumbai- 400051 <b>Script Code: VENUSREM</b>	<b>BSE Limited</b> 25 <sup>th</sup> Floor, Phiroze Jeejeebhoy Towers Dalal Street Mumbai-400051 <b>Script Code: 526953</b>
--	--

**Sub.: Outcome of Board Meeting date 29<sup>th</sup> January 2026**

Dear Sir/ Madam,

This has reference to the meeting of Board of Directors held on 29<sup>th</sup> January 2026 inter alia considered and approved:

1. Unaudited Consolidated and Standalone Financial Results for the quarter and nine months ended on 31<sup>st</sup> December 2025 along with Limited Review report.

Unaudited Financial Results for the quarter and nine months ended on 31<sup>st</sup> December 2025 along with Limited Review report are enclosed herewith.

Meeting commenced at 02:45 pm and concluded at 5.40 p.m.

Kindly take the above information on your record.

Thanking you.

**Yours faithfully,**  
**for VENUS REMEDIES LIMITED**

**Neha**  
**(Company Secretary)**  
**M. No. F8374**

## **VENUS REMEDIES LIMITED**

**Corporate Office :**

51-52, Industrial Area, Phase- I, Panchkula (Hry.)  
134113, India

**Regd. Office :**

SCO 857, Cabin No. 10, 2nd Floor, NAC, Manimajra,  
Chandigarh (U.T.) 160101, India

Website : [www.venusremedies.com](http://www.venusremedies.com)

[www.vmrindia.com](http://www.vmrindia.com)

email : [info@venusremedies.com](mailto:info@venusremedies.com)

CIN No. : L24232CH1989PLC009705

**Unit-I :**

51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India  
Tel. : +91-172-2933090, 2933094, Fax : +91-172-2565566

**Unit-II :**

Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),  
Bhatoli Kalan, Baddi (H.P.) 173205, India  
Tel. : +91-1792-242100, 242101

**Unit-V :**

VENUS PHARMA GmbH  
AM Bahnhof 1-3, D-59368,  
Werne, Germany





# J.K JAIN & ASSOCIATES

## CHARTERED ACCOUNTANTS

S.C.O. 1136-37, Sector 22-B Chandigarh-160022,  
0172-2704536-37,

Email:- [jkjcaps@rediffmail.com](mailto:jkjcaps@rediffmail.com)

### Independent Auditor's Limited Review Report on Quarterly Unaudited Standalone Financial Results of Venus Remedies Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To

The Board of Directors

**VENUS REMEDIES LIMITED**

1. We have reviewed accompanying statement of unaudited standalone financial results of **VENUS REMEDIES LIMITED** ("the Company"), for the Quarter ended 31<sup>st</sup> December 2025 ("the Statement"), being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement which is responsibility of company's Management has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) for Interim Financial Reporting, prescribed, under Section 133 of the Companies Act, 2013, as amended read with relevant rules issued thereunder; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India. Our responsibility is to report a conclusion on these statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.



## 5. Emphasis of matter:

1. We draw attention to Note 4 of the accompanying Statement, which describes the financial condition of the Company's overseas wholly owned subsidiary, *Venus Pharma GmbH*. As stated in the note, the subsidiary's net worth has turned negative by INR 94.15 Lakhs as at the reporting date, which indicates the existence of a material uncertainty that may cast significant doubt on its ability to continue as a going concern.

We have considered management's assessment of the going concern assumption, including their future projections, proposed financial support from the holding company, revival strategies and representations obtained that the subsidiary's financial position is expected to improve and stabilize by the end of the financial year 2025-26.

2. We draw attention to Note 5 of the accompanying Statement, which describes the outstanding share application money amounting to INR 2,859.72 Lakhs in respect of *Venus Pharma GmbH*, a wholly owned subsidiary of the Company. The share allotment against this amount has been pending as it is not mandatory under the applicable laws of Germany.

Management has represented that they consider this investment strategic in nature and that the parent company intends to recover this amount in due course as a result of the restructuring of European operations carried out by the Management in FY 2025-26. Although the subsidiary is currently facing financial challenges, the Company has reiterated its intention to provide the necessary financial and operational support during the transition period.

Our conclusion is not modified in respect of these matters.

**For J.K Jain & Associates**  
**Chartered Accountants**  
**FRN-004025N**



**CA Anurag Verma**  
**Partner**  
**M. No. 555033**  
**UDIN: 26555033LWTZLG3801**  
**Date: 29<sup>th</sup> January, 2026**




**STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON  
31ST DECEMBER 2025**

(Rs. In Crores except EPS)

S. No.	PARTICULARS	QUARTER ENDED ON			NINE MONTHS ENDED ON		YEAR ENDED ON
		31/12/2025	30/09/2025	31/12/2024	31/12/2025	31/12/2024	31/03/2025
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	<b>Revenue</b>						
	(a) Revenue from Operations	179.95	192.65	172.20	509.73	447.74	644.47
	(b) Other Income	2.41	1.68	2.08	6.81	11.69	15.77
	<b>Total Income</b>	<b>182.36</b>	<b>194.33</b>	<b>174.28</b>	<b>516.54</b>	<b>459.42</b>	<b>660.24</b>
2	<b>Expenses</b>						
	(a) Cost of Material Consumed	93.86	106.51	97.61	271.70	244.61	348.82
	(b) Purchase of stock in trade	1.90	1.87	5.50	6.03	22.91	25.04
	(c) Changes in Inventories of finished goods, work -in -progress & Stock in Trade	(9.51)	(1.06)	2.38	(10.02)	4.93	0.93
	(d) Employee benefits expense	19.94	22.03	17.39	61.23	52.92	72.24
	(e) Depreciation & amortization expense	6.32	5.92	5.20	18.19	17.13	21.62
	(f) Selling ,Manufacturing and Administrative expenses	32.84	28.43	23.34	83.65	62.83	104.15
	(g) Research & Development expenses	4.20	5.03	3.41	12.64	9.78	18.29
	<b>Total Expense</b>	<b>149.55</b>	<b>168.73</b>	<b>154.83</b>	<b>443.42</b>	<b>415.11</b>	<b>591.09</b>
3	<b>Profit before taxes ( 1-2 )</b>	<b>32.81</b>	<b>25.60</b>	<b>19.45</b>	<b>73.12</b>	<b>44.32</b>	<b>69.15</b>
4	<b>Exceptional Items</b>	-	-	9.91	-	9.91	9.91
5	<b>Profit after exceptional items ( 3 + 4 )</b>	<b>32.81</b>	<b>25.60</b>	<b>29.36</b>	<b>73.12</b>	<b>54.23</b>	<b>79.06</b>
	<b>EBIDTA (3+2e)</b>	<b>39.13</b>	<b>31.52</b>	<b>24.65</b>	<b>91.31</b>	<b>61.45</b>	<b>90.77</b>
6	<b>Tax Expenses</b>						
A	Current Tax	8.25	6.45	7.38	18.40	13.65	18.93
B	Deferred Tax	(0.36)	(0.09)	(2.10)	(1.15)	2.81	4.65
C	Tax expense related to previous year	-	-	-	-	-	2.93
7	<b>Net Profit /( Loss) for the period ( 5 - 6 )</b>	<b>24.92</b>	<b>19.24</b>	<b>24.08</b>	<b>55.87</b>	<b>37.77</b>	<b>52.55</b>
8	<b>Other Comprehensive Income</b>						
A	(I) Items that will not be reclassified to Profit & loss	(0.03)	(0.12)	(0.05)	(0.27)	(0.14)	(0.48)
B	(I) Items that may be reclassified to Profit & loss	2.22	0.63	(2.80)	6.58	0.39	0.05
	(II) Income tax relating to items that may be reclassified to Profit & loss	-	-	0.74	-	(0.06)	-
C	Total other comprehensive Income Net of Income Tax	2.19	0.51	(2.11)	6.31	0.18	(0.43)
9	<b>Total comprehensive Income for the period (7+/-8)</b>	<b>27.11</b>	<b>19.75</b>	<b>21.97</b>	<b>62.18</b>	<b>37.95</b>	<b>52.12</b>
10	<b>Paid up equity share capital ( Face Value of Equity Shares)</b>	<b>13.37</b>	<b>13.37</b>	<b>13.37</b>	<b>13.37</b>	<b>13.37</b>	<b>13.37</b>
11	<b>Other Equity</b>	<b>10</b>	<b>10</b>	<b>10</b>	<b>10</b>	<b>10</b>	<b>10</b>
12	<b>Earning per share ( of Rs. 10/- each )</b>						<b>576.13</b>
	(a) Basic (₹)	18.64	14.40	18.02	41.79	28.25	39.32
	(b) Diluted (₹)	18.64	14.40	18.02	41.79	28.25	39.32



For **VENUS REMEDIES LIMITED**  
  
**CHAIRMAN & MANAGING DIRECTOR**

DIN - 00435503




**Notes to the standalone financial results: -**

1. The above Standalone Financial Results have been reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on 29<sup>th</sup> January 2026. The statutory auditors of the company have carried out limited review of the above Standalone Financial Result for the quarter and nine months ended 31st December 2025, pursuant to Regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015.
2. The Standalone Financial Results are prepared in accordance with recognition and measurement principles laid down in the Indian Accounting Standards as prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India.
3. The company has a wholly owned subsidiary named Venus Pharma GmbH in Germany and step-down subsidiary of Venus Pharma GmbH named as Venus Pharma Kft in Hungary.
4. Net worth of the Company's overseas wholly owned subsidiary, *Venus Pharma GmbH*, has been eroded by INR 94.15 Lakhs. But management's assessment for the going concern assumption, including future projections, proposed financial support and revival strategies, the subsidiary's financial position is expected to improve and stabilize by the end of the financial year 2025-26.
5. The share application amounts to INR 2,859.72 Lakhs in respect of Venus Pharma GmbH, a wholly owned subsidiary of the Company is pending for allotment of shares as share allotment against this amount is not a regulatory requirement under the applicable laws of Germany. The Management has reiterated that they consider this investment strategic in nature and that the parent company intends to recover this amount in due course as a result of the restructuring of European Operations it carried out in FY25.
6. Previous year / period figures have been regrouped/ reclassified wherever necessary.
7. The group has only one reportable segment namely "Pharmaceuticals"

**For and on behalf of Board of Directors  
for VENUS REMEDIES LIMITED**



**Date: 29-01-2026**



**Pawan Chaudhary**

**(Managing Director)**

**DIN: 00435503**



# J.K JAIN & ASSOCIATES

## CHARTERED ACCOUNTANTS

S.C.O. 1136-37, Sector 22-B Chandigarh-160022,  
0172-2704536-37,

Email:- [jkjcaps@rediffmail.com](mailto:jkjcaps@rediffmail.com)

### Independent Auditor's Limited Review Report on Unaudited Quarterly Consolidated financial results of Venus Remedies Limited pursuant to the regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 as amended

To  
The Board of Directors  
VENUS REMEDIES LIMITED

1. We have reviewed the accompanying statement of unaudited consolidated financial results of **VENUS REMEDIES LIMITED ("the Holding Company")** and its subsidiary (**collectively referred to as 'the Group'**), for the Quarter ended 31<sup>st</sup> December, 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following Subsidiary:
  - i. Venus Pharma GmbH
  - ii. Venus Pharma Kft (Subsidiary of Venus Pharma GmbH)





5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the report of referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

## 6. **Emphasis of matter**

1. We draw attention to Note 4 of the accompanying Statement, which describes the financial condition of the Company's overseas wholly owned subsidiary, *Venus Pharma GmbH*. As stated in the note, the subsidiary's net worth has turned negative by INR 94.15 Lakhs as at the reporting date, which indicates the existence of a material uncertainty that may cast significant doubt on its ability to continue as a going concern.

We have considered the management's assessment of the going concern assumption, including their future projections, proposed financial support from the holding company, and revival strategies. Based on representations obtained and the disclosures made in the Statement, management is of the view that this is a temporary phase and the subsidiary's financial position is expected to improve and stabilize by the end of the financial year 2025–26.

2. We draw attention to Note 5 of the accompanying Statement, which describes the outstanding share application money amounting to INR 2,859.72 Lakhs in respect of *Venus Pharma GmbH*, a wholly owned subsidiary of the Company. The share allotment against this amount has been pending as it is not mandatory under the applicable laws of Germany.

Management has represented that they consider this investment strategic in nature and that the parent company intends to recover this amount in due course as a result of the restructuring of European operations carried out by the Management in FY 2025-2026. Although the subsidiary is currently facing financial challenges, the Company has reiterated its intention to provide the necessary financial and operational support during the transition period.

Our opinion is not modified in respect of above matters.

## 7. **Other Matter**

The accompanying statement of quarterly unaudited standalone financial results includes the unaudited interim financial results and other financial information in respect of two subsidiaries, whose financial result and other information without giving the effect to the elimination of the intra group transaction reflect groups as:




<b>Name of Subsidiary</b>	<b>Revenue (INR in Crores)</b>	<b>Net Profit/(Loss) (INR in Crores)</b>	<b>Total comprehensive Income (INR in Crores)</b>
<b>Venus Pharma GmbH</b>	17.16	(0.53)	(0.53)
<b>Venus Pharma Kft</b>	Nil	Nil	Nil

Further, subsidiary is located outside India, whose financial results have been prepared in accordance with accounting principles generally accepted in India, and which have been reviewed by us under standard of auditing applicable in India. Our opinion, in so far as it relates to the balances and affairs of the subsidiary, is based on our audit report.

Our conclusion on the Statement is not modified in respect of the above matter.

**For J.K Jain & Associates**  
**Chartered Accountants**  
**FRN-004025N**



**CA Anurag Verma**  
**Partner**  
**M. No. 555033**  
**UDIN: 26555033FKUENQ9684**  
**Date: 29<sup>th</sup> January, 2026**



**STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED  
31st DECEMBER 2025**

(Rs. In Crores except EPS)

S. No.	PARTICULARS						
		QUARTER ENDED ON			NINE MONTHS ENDED ON		YEAR ENDED ON
		31/12/2025	30/09/2025	31/12/2024	31/12/2025	31/12/2024	31/03/2025
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	<b>Revenue</b>						
	(a) Revenue from Operations	180.26	192.75	176.52	510.19	455.23	652.89
	(b) Other Income	2.52	1.71	2.37	7.64	11.88	15.95
	<b>Total Income</b>	<b>182.78</b>	<b>194.46</b>	<b>178.89</b>	<b>517.83</b>	<b>467.11</b>	<b>668.85</b>
2	<b>Expenses</b>						
	(a) Cost of Material Consumed	93.86	106.51	97.52	271.70	244.56	348.77
	(b) Purchase of stock in trade	1.90	1.86	5.50	6.03	22.91	25.04
	(c) Changes in Inventories of finished goods, work-in-progress & Stock in Trade	(9.51)	(1.06)	7.18	(10.02)	8.09	4.81
	(d) Employee benefits expense	20.83	22.97	19.55	64.11	59.33	80.49
	(e) Finance Cost	0.01	0.01	0.01	0.03	0.05	0.07
	(f) Depreciation & amortization expense	6.56	6.17	5.41	18.91	17.79	22.51
	(g) Selling, Manufacturing and Administrative expense	30.93	27.16	24.72	81.44	70.11	107.16
	(h) Research & Development expenses	4.73	4.35	4.03	13.07	13.39	18.08
	<b>Total Expense</b>	<b>149.31</b>	<b>167.97</b>	<b>163.92</b>	<b>445.27</b>	<b>436.23</b>	<b>606.93</b>
3	<b>Profit before taxes ( 1-2 )</b>	<b>33.47</b>	<b>26.49</b>	<b>14.97</b>	<b>72.56</b>	<b>30.89</b>	<b>61.92</b>
4	<b>Exceptional Items</b>	-	-	9.91	-	9.91	9.91
5	<b>Profit after exceptional items ( 3 + 4 )</b>	<b>33.47</b>	<b>26.49</b>	<b>24.88</b>	<b>72.56</b>	<b>40.80</b>	<b>71.83</b>
	<b>EBIDTA (3+2e+2f)</b>	<b>40.04</b>	<b>32.67</b>	<b>20.39</b>	<b>91.50</b>	<b>48.73</b>	<b>84.49</b>
6	<b>Tax Expense</b>						
A	Current Tax	8.25	6.45	7.38	18.40	13.65	18.93
B	Deferred Tax	(0.36)	(0.09)	(2.10)	(1.15)	2.81	4.65
C	Tax expense related to previous year	-	-	-	-	-	2.93
7	<b>Net Profit /( Loss) for the period ( 5 - 6 )</b>	<b>25.58</b>	<b>20.13</b>	<b>19.60</b>	<b>55.31</b>	<b>24.34</b>	<b>45.32</b>
8	<b>Other Comprehensive Income</b>						
A	(I) Items that will not be classified to profit & loss	(0.03)	(0.12)	(0.05)	(0.27)	(0.14)	(0.48)
B	(I) Foreign Currency Translation Reserve	(0.29)	0.74	0.36	(0.80)	(0.05)	(0.25)
C	(I) Items that will be classified to profit & loss	2.22	0.63	(2.80)	6.58	0.39	0.05
	(II) Income tax relating to items that may be reclassified to Profit & loss	-	-	0.74	-	(0.06)	-
	Total other comprehensive Income Net of Income Tax	1.90	1.26	(1.75)	5.51	0.13	(0.68)
9	<b>Total comprehensive Income for the period (7+/-8)</b>	<b>27.48</b>	<b>21.39</b>	<b>17.85</b>	<b>60.82</b>	<b>24.47</b>	<b>44.64</b>
10	<b>Paid up equity share capital ( Face Value of Equity Shares)</b>	<b>13.37</b>	<b>13.37</b>	<b>13.37</b>	<b>13.37</b>	<b>13.37</b>	<b>13.37</b>
		10	10	10	10	10	10
11	<b>Other Equity</b>	-	-	-	-	-	547.58
12	<b>Earning per share ( of Rs. 10/- each )</b>						
	(a) Basic	19.14	15.06	14.66	41.37	18.20	33.90
	(b) Diluted	19.14	15.06	14.66	41.37	18.20	33.90



For VENUS REMEDIES LIMITED

CHAIRMAN & MANAGING DIRECTOR

DIN- 00435503



**Notes to the consolidated financial results: -**

1. The above Consolidated Financial Results have been reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on 29th January 2026. The statutory auditors of the holding company have carried out limited review of the above Consolidated Financial Result for the quarter and nine months ended 31st December 2025, pursuant to Regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015.
2. The Consolidated Financial Results are prepared in accordance with recognition and measurement principles laid down in the Indian Accounting Standards as prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India.
3. The parent company has a wholly owned subsidiary named Venus Pharma GmbH in Germany. Venus Pharma Kft is a step-down subsidiary of the parent company through Venus Pharma GmbH. The consolidated financial results include the results of both Venus Pharma GmbH and its step-down subsidiary Venus Pharma Kft.
4. The net worth of the Parent Company's overseas wholly owned subsidiary, *Venus Pharma GmbH*, has been eroded by INR 94.15 lakhs. But management's assessment for the going concern assumption, including future projections, proposed financial support and revival strategies, the subsidiary's financial position is expected to improve and stabilize by the end of the financial year 2025-26.
5. The share application amounts to INR 2859.72 Lakhs in respect of Venus Pharma GmbH, a wholly owned subsidiary of the Parent Company is pending for allotment as share allotment against this amount is not a regulatory requirement under the applicable laws of Germany. The Management has reiterated that they consider this investment strategic in nature and that the parent company intends to recover this amount in due course as a result of the restructuring of European Operations it carried out in FY25.
6. Previous year / period figures have been regrouped/ reclassified wherever necessary.
7. The group has only one reportable segment namely "Pharmaceuticals"



**Date: 29.01.2026**

**For and on behalf of Board of Directors  
for VENUS REMEDIES LIMITED**

  
**Pawan Chaudhary**

**(Managing Director)**

**DIN: 00435503**